List of Xenleta drug patents

Xenleta is owned by Nabriva.

Xenleta contains Lefamulin Acetate.

Xenleta has a total of 3 drug patents out of which 0 drug patents have expired.

Xenleta was authorised for market use on 19 August, 2019.

Xenleta is available in solution;intravenous dosage forms.

Drug patent challenges can be filed against Xenleta from August, 2028.

The generics of Xenleta are possible to be released after 23 May, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8153689 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Mar, 2028

(5 years from now)

US8071643 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Jan, 2029

(5 years from now)

US9120727 NABRIVA Process for the preparation of pleuromutilins
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 19, 2024
Generating Antibiotic Incentives Now (GAIN) Aug 19, 2029

Drugs and Companies using LEFAMULIN ACETATE ingredient

NCE-1 date: August, 2028

Market Authorisation Date: 19 August, 2019

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in